A study to determine the effect of post-infusion scalp cooling time in the high dose FEC-regime

Completed

• Conditions: alopecia; hair loss; 10006291

• Registration Number: NL-OMON40042
• Lead Sponsor: Medisch Centrum Alkmaar

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 130

Inclusion Criteria

Intravenous administered FEC or FEC-D (docetaxel) regimen with an epirubicine dose of 90 mg/m2 or more at 3-weekly intervals, age 18 years or more, written informed consent

Exclusion Criteria

boldness before the start of the study,hematological malignancies with generalized haematogenic metastases and if in those conditions chemotherapy is given with a curative intent, clinical signs of sclap metastases

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Amount of hair loss</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1 Acceptability of scalp cooling<br /><br>2 Relation of the efficacy of scalp cooling with prior<br /><br>chemotherapy/radiotherapy or hormonal treatment, liver- or kidney function<br /><br>disorder and type of hair.<br /><br>3 Quality Of Life during chemotherapy </p><br>